NMN
Best-in-class: NMN
A direct NAD+ precursor (one step from NAD+) popular for cellular energy and longevity — an alternative to NR for raising NAD+.
NMN quick facts
| Suggested dose | 250–1,000 mg daily. |
| How often | Daily |
| Who it's for | NAD+, energy and metabolic-aging experimenters (an NR alternative). |
| Best-in-class brand | NMN |
Popular partly because it sounds one step closer to the destination, which may not be how it actually behaves in the body. Treat it as roughly interchangeable with NR until the transporter question is settled, and buy on price and purity rather than on the step-count argument. Worth knowing that its regulatory status as a supplement in the US has been contested, which affects availability and makes third-party testing more important than usual here. Same caution around active malignancy as NR.
How NMN actually works
NMN sits one enzymatic step from NAD+ — NMN adenylyltransferase converts it directly — which is the basis for the claim that it's the more efficient precursor. The genuine scientific argument is whether it enters cells intact at all: NMN is phosphorylated and therefore not obviously membrane-permeable, and much evidence suggests it's dephosphorylated to nicotinamide riboside outside the cell, absorbed, then re-phosphorylated inside. A dedicated NMN transporter has been proposed but remains debated. If the conversion route is real, NMN and NR are closer to the same product than the marketing suggests.
Where to get NMN
Find NMN on iHerb →The evidence for NMN
Graded by what exists behind each claim.
✅ Clinically validated
- RCTs show NMN raises blood NAD+ and improved some measures of muscle/aerobic performance and insulin sensitivity.
- Human functional-outcome data are growing but still early.
📊 Correlative data
- NAD+ declines with age, tracking with metabolic and mitochondrial aging.
🧪 Theoretical / extrapolated benefits
- The NAD+/sirtuin longevity promise is strong in animals; human healthspan outcomes remain unproven. (Note: NMN's supplement status has faced regulatory uncertainty in the US.)
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What NMN actually does
Nicotinamide mononucleotide is one enzymatic step from nicotinamide adenine dinucleotide, and that fact is the entire marketing claim and also the weakest part of it. Nicotinamide mononucleotide adenylyltransferase converts it to NAD+ in a single reaction. The problem is the step before: NMN is a phosphorylated nucleotide of about 334 daltons, and a charged phosphate is not a structure that crosses membranes freely.
Which is why the transport question is the mechanistic center of this page. The route most consistent with the data is dephosphorylation to nicotinamide riboside at the cell surface, uptake, and rephosphorylation inside -- meaning the molecule that enters is arguably not the molecule that was swallowed. The precursor literature has framed this as a question of whether the various NAD+ precursors are meaningfully distinct or redundant Cantó 2022.
The comparison molecule has cleaner human data on exactly this point. Nicotinamide riboside was shown to be orally bioavailable in mice and humans with the exposure demonstrated rather than inferred Trammell 2016. That is the standard NMN has to meet, and it is why 'one step closer' is a statement about a metabolic map rather than about a person.
The clock here is not a half-life, it is a turnover rate, and it is fast. Cellular NAD+ is consumed continuously by PARPs, sirtuins and CD38 and resynthesized through the salvage pathway; the pool recycles many times a day. A once-daily capsule is a brief input into a rapidly turning pool, which is a different proposition from raising a slow reservoir.
Cell, rodent, human — and where it stops
The human trials now exist, and what they measure is the interesting part.
What has been measured in people. A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial examined efficacy and safety in healthy middle-aged adults Yi 2023. A randomized, double-blind, placebo-controlled trial measured NAD metabolism and arterial stiffness after long-term supplementation Katayoshi 2023. Safety of oral administration has been evaluated in healthy adult men and women Fukamizu 2022, and systematic reviews with meta-analysis have pooled the glucose and lipid outcomes Zhang 2024 and the safety and metabolism-related outcomes Yang 2026.
The first obstacle is that the primary endpoint is usually the precursor's own marker. Blood NAD+ rising is the demonstration that the pathway is intact, not that anything downstream changed. Work toward personalized supplementation is explicitly organized around NAD concentration as the thing being targeted Kuerec 2024, which is an honest framing and also a surrogate one.
The second obstacle is that the marker may not vary the way the field assumed. Human whole-blood NAD+ levels have been reported not to vary with age or with lifestyle interventions Tretowicz 2026. If the deficit the product is sold to correct is not visible in the compartment being measured, the rationale needs restating rather than repeating.
What would close the gap. Report tissue NAD+ rather than whole blood, pre-specify a functional endpoint, and compare NMN directly against nicotinamide riboside and against plain nicotinamide at matched molar doses Cantó 2022 Trammell 2016.
NMN — which form, and does it matter
The comparison that matters is not between brands of NMN, it is between NMN, nicotinamide riboside and nicotinamide. All three feed the same salvage pathway. The precursor review asks directly whether the distinctions are meaningful or redundant Cantó 2022, and nicotinamide riboside is the one with a demonstrated human oral bioavailability study Trammell 2016.
Sublingual, liposomal and enteric forms all exist because of the phosphate. Each is an attempt to solve the same problem -- getting a charged nucleotide somewhere useful -- and none of them has a published head-to-head human exposure comparison against plain oral powder Kuerec 2024.
Purity is a live issue in this category. NMN is synthesized rather than extracted, and a certificate of analysis naming the assay method is the only thing distinguishing a tested product from an untested one. That matters more here than in a botanical because there is no marker chemistry to fall back on.
The regulatory position is part of the form question in the United States. The Food and Drug Administration has taken the view that NMN is excluded from the dietary supplement definition because it was investigated as a drug, so availability and labeling may change. No filed panel for an NMN product has been read into supplements_data.BLENDS on this site.
What would have to be true, and how you would know it was not
1. The marker prediction, at 8 weeks. Whole-blood NAD+ at baseline and 8 weeks at 500 mg daily. Predict a rise, because that is the reproducible finding across the trials Yi 2023 Katayoshi 2023. Predict also that this tells you the pathway works and nothing about a clinical outcome.
2. The baseline prediction, which cuts against the anti-aging pitch. Predict that baseline whole-blood NAD+ does not correlate with age in a healthy sample, because that is the reported finding Tretowicz 2026. A product sold to reverse an age-related decline should be able to demonstrate the decline first.
3. The functional prediction, at 12 weeks. Fasting glucose and insulin with a calculated insulin sensitivity index, plus a six-minute walk or a grip measurement. Predict small and inconsistent changes, which is what the pooled analyses of glucose and lipid metabolism describe Zhang 2024 Yang 2026.
4. The vascular prediction. Pulse wave velocity at baseline and after long-term dosing, which is the endpoint the arterial stiffness trial used Katayoshi 2023.
5. The precursor falsification. Randomize NMN against nicotinamide riboside against plain nicotinamide at matched molar doses, measuring blood NAD+ and one functional endpoint. Prediction: the three are hard to separate on the marker Cantó 2022 Trammell 2016. If NMN clearly wins, the premium is justified and this section is wrong.
What nobody has tested yet
Nobody has demonstrated intact NMN uptake in human tissue. The transport route is inferred, and the human oral bioavailability demonstration that exists belongs to nicotinamide riboside Trammell 2016.
Nobody has measured tissue NAD+ in a supplementation trial. Whole blood is the accessible compartment and it may not be the relevant one Tretowicz 2026 Kuerec 2024.
Nobody has run it for years. The trials are weeks to months Yi 2023 Fukamizu 2022 Yang 2026, so nothing can be said about daily use over a decade.
And nobody has resolved the proliferation question. NAD+ precursors support cell proliferation, and whether that matters in somebody with an undiagnosed malignancy is unresolved rather than settled in either direction Cantó 2022.
NMN — its own safety story, not its category's
Short-term tolerability is good and the honest statement is about the length of the record rather than its content. Safety evaluation of oral administration in healthy adults reported it well tolerated Fukamizu 2022, and the pooled safety and metabolism-related outcomes reach the same conclusion across the available trials Yang 2026. Nausea, flushing and headache are the usual reports.
The theoretical concern worth stating plainly is proliferation. NAD+ is required for the DNA repair and metabolic machinery of dividing cells, so a precursor supports proliferation in general rather than selectively Cantó 2022. Whether that matters in a person with an undiagnosed cancer has not been studied, which is a gap rather than an alarm and is the reason it belongs on the page.
The regulatory status is contested in the United States. The Food and Drug Administration's position that NMN is excluded from the supplement definition means availability, labeling and enforcement may change. That is a purchasing consideration and not a safety finding, and confusing the two helps nobody.
What has not been established. No trial has run for years Yi 2023 Katayoshi 2023, none has enrolled pregnancy, and none has characterized interactions with medication. Anyone with a cancer history should be making this decision with their oncology team. Nothing here is medical advice or a diagnosis, and none of these statements has been evaluated by the Food and Drug Administration.
Sources read for this page
- Yi L. The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Geroscience 2023 · PMID 36482258
- Katayoshi T. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. Sci Rep 2023 · PMID 36797393
- Zhang J. Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials. Crit Rev Food Sci Nutr 2024 · PMID 39116016
- Kuerec AH. Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration. Mech Ageing Dev 2024 · PMID 38430946
- Fukamizu Y. Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep 2022 · PMID 36002548
- Yang W. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis. Nutrients 2026 · PMID 42514320
- Tretowicz MM. Human whole-blood NAD+ levels do not vary with age or lifestyle interventions. Nat Metab 2026 · PMID 42135539
- Cantó C. NAD+ Precursors: A Questionable Redundancy. Metabolites 2022 · PMID 35888754
- Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications 2016 · PMID 27721479
How you would know if it worked
Nobody observes their own lifespan, so the longevity claim here is not one you can test — and saying that plainly is more use than any sirtuin diagram. The trial claim is narrower and it is a number. NMN trials report improved insulin sensitivity, so fasting insulin is the read-out and HbA1c is the three-month average that says whether better sensitivity turned into better control. Homocysteine sits alongside as the cost line, because nicotinamide leaves the body methylated and a dose that outruns your methyl supply shows up there rather than in how you feel. Twelve weeks, three numbers, and a null is a real result at this price.
- Fasting Insulin Retest: Every 3–6 months, or 8–12 weeks after an intervention.
- HbA1c (Hemoglobin A1c) Retest: Every 3 months (matches red cell lifespan).
- Homocysteine Retest: 8–12 weeks after starting B vitamins.
The cheapest panel carrying Fasting Insulin and at least one other of these is Am I Prediabetic?, at $19 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
NMN — safety & side effects
- Well tolerated in the trials to date — nausea, flushing and headache are the usual reports.
- Its US regulatory status is contested: the FDA has taken the position that NMN is excluded from the supplement definition because it was investigated as a drug. Availability may change.
- The theoretical concern worth stating: NAD+ precursors fuel cell proliferation, and whether that matters in someone with an undiagnosed cancer is unresolved rather than settled either way.
The same on every page it applies to. Read it here; it is not repeated research.
- Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
Build your foundation with Coach Cam
The full Supplement Vault — 371 products across 14 categories with clinical, correlative & theoretical evidence, plus my Thorne partner links — lives inside Skool alongside 278 peptides.
Join Skool — $10/mo →Bloodwork to run alongside NMN
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation, the process most NAD claims route through |
| HbA1c (Hemoglobin A1c) | Metabolic health — the best-supported half of the NAD story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Where a real metabolic effect would show |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
NMN — frequently asked questions
What is NMN?
A direct NAD+ precursor (one step from NAD+) popular for cellular energy and longevity — an alternative to NR for raising NAD+.
What is the suggested dose of NMN?
250–1,000 mg daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
What are the researched benefits of NMN?
RCTs show NMN raises blood NAD+ and improved some measures of muscle/aerobic performance and insulin sensitivity.
Who is NMN for?
NAD+, energy and metabolic-aging experimenters (an NR alternative).
Where can I buy NMN?
Coach Cam sources NMN from vetted, top-rated brands on iHerb — use the buy link on this page.
NMN inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What NMN is used for
NMN appears under 4 goals in the goal router.
Related Longevity & Antioxidants supplements
Where this goes next
NMN is the nad+ arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.